Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin on Visceral Hypersensitivity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects aged 18-75 years old inclusive~* Meet Rome IV criteria for IBS-D or IBS-M~* Subjects should report urgency with bowel movement at least once a week~* If subjects are ≥50 years old, a colonoscopy must have been completed within the past 5 years~* Subjects are capable of understanding the requirements of the study, are willing to comply with all the study procedures, and are willing to attend all study visits.~* Agree to use an acceptable method of contraception throughout their participation in the study. Acceptable methods of contraception include: double barrier methods (condom with spermicidal jelly or a diaphragm with spermicide); hormonal methods (e. g. oral contraceptives, patches or medroxyprogesterone acetate); or an intrauterine device (IUD) with a documented failure rate of less than 1% per year. Abstinence or partner(s) with a vasectomy may be considered an acceptable method of contraception at the discretion of the investigator.~* All subjects will provide Institutional Review Board (IRB)-approved informed written consent prior to beginning any study-related activities~NOTE: Female subjects who have been surgically sterilized (e.g. hysterectomy or bilateral tubal ligation) or who are postmenopausal (total cessation of menses for \>1 year) will not be considered females of childbearing potential.~Exclusion Criteria:~* Treatment with antibiotics or Xifaxan in the last two months~* Subjects with history of intestinal surgery (except appendectomy or cholecystectomy)~* Subjects with known pelvic floor dysfunction~* Pregnancy~* Nursing mothers~* Poorly controlled/uncontrolled significant medical condition that would interfere with study procedures~* History of bowel obstruction~* History of celiac disease~* History of inflammatory bowel disease~* Cirrhosis~* IBS-C/chronic idiopathic constipation~* Diabetes~* History of anorectal radiation/surgery~* History of prostatitis~* Known allergy or hypersensitivity to rifaximin or rifamycin~* Current treatment with eluxadoline or opiates~NOTE: Development of any of the exclusion criteria during the study will be considered a basis for subject discontinuation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Therapeutic (Type: EXPERIMENTAL): 40 subjects with diarrhea-predominant IBS (IBS-D) or mixed IBS (IBS-M) will be enrolled in the study. At the first clinic visit, subjects will undergo rectal sensitivity testing, as well as lactulose breath testing. Subjects will be asked to record their symptoms and bowel habits in a diary over the next 7 days. During the second clinic visit, subjects will receive a 14-day course of rifaximin (550 mg PO TID). During these 14 days, subjects will record their symptoms and bowel habits. Subjects will return to the clinic after completion of the medication and will undergo repeat evaluation via rectal sensitivity testing to assess for change in rectal sensitivity.

Based on this trial design, predict the completion outcome and termination type (if applicable).